Tham (tromethamine) dosing, indications, interactions, adverse effects, and more , , , Tham (tromethamine) dosing, indications, interactions, adverse effects, and more, , , , , , , , , , , , , , , , , Edition:EnglishFrançaisDeutsch, Search, , No Results, News & Perspective, Drugs & Diseases, CME & Education, Log In, Register, , , , , https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cDovL3JlZmVyZW5jZS5tZWRzY2FwZS5jb20vZHJ1Zy90aGFtLXRyb21ldGhhbWluZS0zNDI4ODQ=, , , processing.... , , , , , tromethamine (Rx)Brand and Other Names:Tham, Classes: Alkalinizing Agents, , Dosing & Uses, Adverse Effects, Warnings, Pregnancy, Pharmacology, Administration, Images, Patient Handout, Formulary, Dosing & Uses, AdultPediatric, Dosage Forms & Strengths, , infusion solution, , 0.3M, , , more... Alkalinizing Agent, , Tham Solution (mL of 0.3 M) required = Body Weight (kg) x Base Deficit (mEq/L) x 1.1 given by IV infusion, , Cardiac arrest with metabolic acidosis: IV 3.6-10.8 g, maximum 500 mg/kg/dose, , Cardiac arrest with metabolic acidosis if chest open: 2-6 g injected directly into ventricular cavity, avoid cardiac muscle, , Cardiac bypass surgery with acidosis: 9 mL/kg IV, maximum 500 mg/kg, , As adult, Adverse Effects, , Frequency Not Defined, , Alkalosis, , Hypervolemia, , Venospasm, , Hyperkalemia, , Hypoglycemia (usu doses >500 mg/kg over <1hr), , Hepatic necrosis (resulted during delivery via umbilical venous catheter), , Necrosis with extravasation, , Phlebitis, , Tissue irritation, , Apnea, , Pulmonary edema, , Respiratory depression, , , Warnings, , Contraindications, , Uremia, , Anuria, , Neonates: chronic respiratory acidosis, salicylate intoxication, , , Cautions, , Renal impairment, , Extravasation may cause inflammation & tissue necrosis, , Administer slowly to avoid alkalosis, , Risk of overhydration, that may cause serum electrolyte dilution, pulm edema, CHF, , Risk of hypoglycemia in preemies & neonates, , , Pregnancy & Lactation, , Pregnancy Category: C, , Lactation: not known if present in breast milk, use caution, , Pregnancy Categories, A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA:Information not available. more... Pharmacology, , Metabolism: N/A, , Excretion: urine, , Mechanism of Action, , Basic chemical, pHed to 8.6 w/ acetic acid, , , Administration, , IV Administration, , Slow intravenous infusion, by addition to pump-oxygenator ACD blood or other priming fluid or by injection into ventricular cavity during cardiac arrest, , If infused into peripheral vein, use large needle in largest antecubital vein or indwelling catheter placed in large vein of an elevated limb to minimize chemical irritation of alkaline solution, , Catheters recommended. , , Storage, , Contains no preservatives/antibacterials; discard unused portion, , , Images, , Patient Handout, Print w/ Office Info, Print w/out Office Info, , Formulary, FormularyPatient Discounts, To view formulary information first create a list of plans. Your list will be saved and can be edited at any time. Create Your List of Plans, Adding plans allows you to:, View the formulary and any restrictions for each plan. Manage and view all your plans together – even plans in different states. Compare formulary status to other drugs in the same class. Access your plan list on any device – mobile or desktop. The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. View explanations for tiers and restrictions, Tier, Description, 1, This drug is available at the lowest co-pay. Most commonly, these are generic drugs. 2, This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs. 3, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs. 4, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 5, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 6, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. NC, NOT COVERED, – Drugs that are not covered by the plan. Code, Definition, PA, Prior Authorization, Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription. , QL, Quantity Limits, Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered. , ST, Step Therapy, Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription. , OR, Other Restrictions, Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription. , Done, Add or Remove Plans, Plans for , Select State: , Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, , Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, Non-Medicare PlansMedicare Plans, Select a box to add or remove a plan. close, Select a class to view formulary status for similar drugs, CLOSE, Additional Offers, CLOSE, Email to Patient, From:, To:, The recipient will receive more details and instructions to access this offer. By clicking send, you acknowledge that you have permission to email the recipient with this information. Send, CLOSE, Email Forms to Patient, From:,